A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
Suzetrigine (Journavx) is the first non-opioid painkiller to be approved in the US in 20 years. It could help over 80 million ...
Journavx reduces pain by targeting a pain-signaling pathway ... Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on VRTX: Vertex Pharmaceuticals NewsMORE Related Stocks Indices ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
On Thursday, the Food and Drug Administration (FDA) granted approval to Vertex Pharmaceuticals' non-opioid painkiller pill, a new alternative for pain relief that does not carry the risk of addiction.
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...